期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Engineering Cell-Selective Charge-Altering Lipid Nanoparticles for Efficient siRNA Delivery in Vivo
1
作者 Fengrui Yang Lingling Lei +3 位作者 Xiangnan Wang jieling hong Zhenkun Wu Jian-Hui Jiang 《CCS Chemistry》 CSCD 2024年第8期2054-2065,共12页
Lipid nanoparticles(LNPs)have emerged as a powerful platform for RNA delivery;the chemical engineering of LNP for efficient delivery of RNA into cytosol remains critical but challenging.One promising strategy is the u... Lipid nanoparticles(LNPs)have emerged as a powerful platform for RNA delivery;the chemical engineering of LNP for efficient delivery of RNA into cytosol remains critical but challenging.One promising strategy is the use of permanently positively charged lipids,which have been shown to enhance the stability and delivery efficiency of LNPs.However,the resulting strong electrostatic interactions reduced the RNA release capacity from the lipoplexes.Herein,we engineered a hydrogen peroxide(H_(2)O_(2))-triggered charge-altering LNP(CALNP)for efficient small interfering RNA(siRNA)delivery and tumor therapy in mice.The incorporation of phenylboronic acid(PBA)into ionizable lipids generated permanently positively charged lipids.A CALNP with optimal lipid formulations was identified,exhibiting enhanced transfection efficiency with effective lysosomal escape through dual effects of electrostatic interaction and ligand-receptor binding.H_(2)O_(2)-triggered removal of PBA groups regenerated ionizable LNP with reduced positive charges at physiological pH,allowing cell-selective siRNA release in the cytoplasm.Our results demonstrated that CALNPs exhibited improved siRNA transfection and gene silencing efficiency.We also showed potent CALNP activity against the polo-like kinase 1(Plk1)gene by effectively silencing Plk1 mRNA and subsequent suppression of tumor growth.Collectively,these findings highlighted the potential of CALNP as an efficient platform for RNA delivery and tumor therapeutics. 展开更多
关键词 lipid nanoparticles siRNA delivery BIOIMAGING charge-altering cancer therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部